What types of policy changes does Blue Cross & Blue Shield of Mississippi issue?

Blue Cross & Blue Shield of Mississippi regularly publishes coverage updates including prior authorization requirement changes, billing code additions or deletions, plan-type coverage modifications, and clinical policy revisions. PolicyChanges.app monitors these notices and summarizes the impact for providers.

How often does Blue Cross & Blue Shield of Mississippi update its policies?

Blue Cross & Blue Shield of Mississippi typically releases policy bulletins on a rolling basis throughout the year. Our system checks for new updates daily and adds them to this feed as soon as they are identified.

What should I do when Blue Cross & Blue Shield of Mississippi changes a prior authorization policy?

Review each change's effective date and action-required notes. Update your billing and clinical workflows before the effective date to avoid claim denials. Each policy detail page on PolicyChanges.app includes a plain-English summary and action items.

Blue Cross & Blue Shield of Mississippi Policy Changes 2026 | Prior Auth & Coverage Updates

Q: How many Blue Cross & Blue Shield of Mississippi policy changes are tracked here?

This page currently tracks 50 documented Blue Cross & Blue Shield of Mississippi policy changes. New items are added as they are identified.

Blue Cross & Blue Shield of Mississippi Policy Changes & Prior Auth Updates

We track 50 documented policy changes from Blue Cross & Blue Shield of Mississippi across MI, MS. Each entry includes an AI-generated plain-English summary, effective date, affected billing codes, and a direct link to the original Blue Cross & Blue Shield of Mississippi notice. Use the related links below to narrow results by specialty or state, or sign up for a free daily alert to receive new Blue Cross & Blue Shield of Mississippi updates automatically.

High impact

State and School Employees' Health Insurance Plan - Interleukin-5 Antagonist Monoclonal Antibodies

Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026

State and School Employees' Health Insurance Plan has established new medical policy criteria for interleukin-5 antagonist monoclonal antibodies (Cinqair, Fasenra, Nucala) used to treat severe eosinophilic asthma, EGPA, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps. The policy establishes detailed prior authorization requirements including specific age restrictions, diagnostic criteria, blood eosinophil count thresholds, and mandatory trial of conventional therapies before approval.

State and School Employees' Health Insurance Plan - Complement Inhibitors

Complement Inhibitors

GLP-1 Agonist

State and School Employees' Health Insurance Plan - Anti-Rheumatic Biologicals

State and School Employees' Health Insurance Plan - Intravenous Iron Replacement Therapy

Chronic Plaque Psoriasis

Anti-Rheumatic Biologicals

Hidradenitis Suppurativa (HS)

State and School Employees' Health Insurance Plan - Intra-articular Hyaluronan Injections for Osteoarthritis

Ambulance and Medical Transport Services

Three-Dimensional Printed Orthopedic Implants

Computer-Assisted Navigation for Orthopedic Procedure

Non-Pedicle Supplemental Fixation Device for Use in the Non-Cervical Spine

Screening Services and Procedures

Total Hip Arthroplasty (THA) - West Central and North East Region

Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas

Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Hematopoietic Cell Transplantation for Solid Tumors of Childhood

Orthopedic Applications of Platelet-Rich Plasma

Bone Morphogenetic Protein

Negative Pressure Wound Therapy

State and School Employees' Health Insurance Plan - New Drug Approvals and Newly Approved Indications for Currently Available Medications

New Drug Approvals and Newly Approved Indications for Currently Available Medications

State and School Employees' Health Insurance Plan - Interleukin-5 Antagonist Monoclonal Antibodies

State and School Employees' Health Insurance Plan - Botulinum Toxin

Oncologic Applications of Positron Emission Tomography (PET) Scanning

Botulinum Toxin

Magnetic Resonance Imaging (MRI) of the Upper Extremity

Magnetic Resonance Imaging (MRI) of the Spine

Magnetic Resonance Imaging (MRI) of the Lower Extremity

Magnetic Resonance Imaging (MRI) of the Brain and Head

Magnetic Resonance Imaging (MRI) of the Abdomen and Pelvis

Computed Tomography (CAT Scan) and Computed Tomographic Angiography (CTA) of the Chest and Thorax

Computed Tomography (CAT Scan) and Computed Tomographic Angiography (CTA) of Extremity or Joint

Arthroscopic Debridement and Lavage as Treatment of Osteoarthritis of the Knee

Pathogen Panel Testing

Morbid Obesity

Epidural Steroid Injections

Orthopedic Applications of Stem Cell Therapy (Including Allografts and Bone Substitutes Used with Autologous Bone Marrow)

Diagnosis and Treatment of Sacroiliac Joint Pain

Intra-articular Hyaluronan Injections for Osteoarthritis

General Approach to Genetic Testing

Treatment of Autism Spectrum Disorder (ASD)

Blue Cross & Blue Shield of Mississippi Telehealth Coding Policy

Percutaneous Revascularization Procedures for Lower Extremity Peripheral Arterial Disease

Multiple Sclerosis

Oral Oncology

Opioid and Opioid Combination Medications

Preventive Health Services

State and School Employees' Health Insurance Plan - Rituximab Non-Oncology